Tru Niagen

“Longevity has no shortage of molecules with compelling theories. Tru Niagen distinguished itself by doing something more difficult: repeatedly submitting its central proposition to measurement.

“The result is unusually clean. Take nicotinamide riboside and NAD-related metabolites rise. That statement is supported by randomised human evidence, at the dose in the capsule, in a trial of one hundred and forty people, and it has been reproduced by universities that took the company's capsules and nothing else. The difficulty begins with the next sentence. What does that increase ultimately mean for the trajectory of human ageing?

“Start with the capsule, because it is the whole product. Three hundred milligrams of one molecule and three of the plainest excipients in the pharmacopoeia. No stack, no matrix, no second ingredient to take the credit. There is almost nowhere for ambiguity to hide: one active molecule, one declared dose, one principal biological target. In a category that sells fourteen ingredients in a proprietary blend, that is a decision, and the company has held it for a decade while selling stacks under other names.

“Then the molecule. Nicotinamide riboside is a form of vitamin B3 and a precursor to NAD, the coenzyme that sits inside energy metabolism, redox chemistry, sirtuin and PARP activity and the cell's stress responses. NAD metabolism changes with age. How much, in which tissue, by what measurement, varies across the literature, and the honest version of the story is more interesting than the slogan.

“The dose-ranging trial is the spine of the file. Eight weeks, placebo against one hundred, three hundred and one thousand milligrams. Whole-blood NAD up twenty two, fifty one and one hundred and forty two percent within two weeks and held to the end. No flushing. No more adverse events than placebo. The company paid for it and two of its authors worked there, which is disclosed, and which is why the independent replications matter: Colorado at one gram, sixty percent higher NAD in blood cells with NIH money; Copenhagen at two grams; Maastricht at one; Birmingham; Seattle. Every one of them found the same thing in the blood. The molecule reaches its target. That is not nothing. In consumer longevity it is close to unique.

“Now the harder sentence. The independent 2026 systematic review counted thirty three human studies of NAD precursors and concluded that they consistently engage the target and are well tolerated, and that effects on function, metabolism, blood vessels and other healthspan outcomes are heterogeneous and often null. Its phrase: clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive. The Danish trial is the sharpest example. Forty obese, insulin-resistant men, two grams a day, twelve weeks, a full metabolic workup. Nothing moved: not insulin sensitivity, not glucose, not the beta cell, not energy expenditure, not body composition, not the mitochondria in their muscle. Two trials that raised NAD in blood could not raise it in muscle at all. Blood pressure fell in one exploratory look and one conference abstract and stayed put in three trials. The biochemical question is increasingly settled. The clinical question is not.

“The molecule has also gone somewhere most supplements never go. It is in phase three in Parkinson's disease: four hundred and ten patients, one gram a day, a year, completed in 2025, results awaited. At three grams a day for a month it was safe and showed a preliminary clinical signal. That does not mean a three hundred milligram capsule treats Parkinson's, and this file will not let anyone read it that way. It means the molecule is credible enough that serious neurologists are spending years and public money asking.

“Safety is a genuine strength. Two grams a day for twelve weeks, three grams for four weeks, one gram for six months, all without a serious event attributed to the molecule. Homocysteine rose modestly only at three grams. One mouse study raised a flag about breast cancer metastasis that no human data has confirmed or dismissed, and the file records it because a file that only records good news is an advertisement.

“The paperwork is mostly a credit. Two FDA notifications without objection, a GRAS letter, an EFSA opinion, Health Canada licences. An accredited laboratory I could verify in the accreditor's own directory. A lot number on every bottle that returns its certificate. A third-party potency test posted for this exact capsule. There is one warning letter, from November 2020, over social posts about coronavirus, answered the next day, and the file says so. And there is the ordinary carelessness of a large company's website: forty five studies on the site and forty one in the annual report, sixty patents on one page and fifty in the press release, Alkemist here and NSF there.

“Then there is the bottle, and this is where the Standard did something the company will not enjoy reading. Stewardship scored 2.57. Not because the bottle is bad; because nothing whatever is said about it. Not its material, not its recyclability, not a carbon figure, not a waste position, not a sentence in the annual report. The Floor Principle holds that a file is gated by its lowest Circle, and the lowest Circle of the best-measured supplement in this volume is the one nobody at the company has written a page about. The anchors computed Finalist, on a score of 3.70.

“The founder ruled One Bio Star, and the file prints both numbers. The ruling recognises what is in the capsule and what has been measured. It does not pretend the bottle has been accounted for. One page from Niagen Bioscience about its packaging and its footprint would move this file on its own merits, and the Inspectorate would welcome it.

“Tru Niagen has answered the first question unusually well. Can oral nicotinamide riboside meaningfully alter human NAD biology? Yes. The question that separates biochemical mastery from a higher order of recognition is what that alteration ultimately changes. Human science is still answering it, and this company, more than most, is paying for the answer.”